Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + platinum + Endostar in first-line advanced TNBC
ChiCTR-OIC-16009690Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Dec 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and endostar in triple-negative breast cancer (TNBC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
gemcitabineendostar
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR-OIC-16009690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009690.